Yeoncheon

This research investigates a new treatment called HyperQureTM, a laparoscopic renal denervation therapy, for adults with resistant hypertension who take three or more blood pressure medications including a diuretic. The study aims to assess the safety and initial effectiveness of this first-in-human approach, which addresses limitations of existing catheter-based procedures, such as incomplete nerve treatment and risks from blood vessel access. The therapy targets nerves around the renal artery to better control blood pressure in patients whose hypertension remains difficult to manage. The treatment uses the HyperQure Renal Denervation System, which delivers radiofrequency energy through a laparoscopic instrument directly around the renal artery via the retroperitoneal approach. This allows a 360-degree treatment of the artery at preset settings for temperature and duration. Before the procedure, CT angiograms plan the target vessels, including main and branch renal arteries. Ten eligible adults will undergo this laparoscopic denervation under general anesthesia as part of this single-arm study. Participants will be monitored for up to 12 months after the procedure. Assessments include CT angiography, blood tests, office and 24-hour ambulatory blood pressure monitoring, and quality of life evaluations. The primary outcome is the change in 24-hour ambulatory systolic blood pressure from baseline to three months after treatment. Safety and effectiveness will be evaluated throughout the follow-up period to gather initial data on this new treatment for resistant hypertension.